Immunocompromised patients receive weaker protection from COVID-19 vaccination
- 14 July 2023
- 1 min read
Immunocompromised or immunosuppressed patients have shown low or undetectable protection after two doses of the same COVID-19 vaccine.
The OCTAVE trial looks into how clinically at-risk patients respond to infection and vaccination. The study is one of the largest studies in the world into post-COVID vaccination in immunocompromised patients.
Participants with reduced immune system function were infected with the Alpha, Delta and Omicron strains of SARS-CoV-2. They were studied up to one year after their first vaccination.
The research showed the risk of severity and death from COVID-19 was high in a small sub-group of conditions, despite vaccination.
The study recruited 2,686 participants across 20 hospital sites in the UK, including 544 recruited in Oxford.
